Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
143
Frequently Asked Questions
What is Market Cap of Viridian Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Viridian Therapeutics Inc market cap is $1.47B.
What is the 52-week high for Viridian Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Viridian Therapeutics Inc 52 week high is $27.20 as of September 16, 2025.
What is the 52-week low for Viridian Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Viridian Therapeutics Inc 52 week low is $9.90 as of September 16, 2025.
What is Viridian Therapeutics Inc stock price today?
Viridian Therapeutics Inc stock price today is $18.65.
What was Viridian Therapeutics Inc stock price yesterday?
Viridian Therapeutics Inc stock price yesterday was $18.01.
What is the PE ratio of Viridian Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Viridian Therapeutics Inc’s P/E ratio is -4.22.
What is the Price-to-Book ratio of Viridian Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Viridian Therapeutics Inc P/B ratio is 4.5069.
What is the 50-day moving average of Viridian Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Viridian Therapeutics Inc 50-day moving average is $17.83.
How many employess does Viridian Therapeutics Inc has?